Description

CJC-1295 is a tetrasubstituted peptide designed to mimic the action of growth hormone-releasing hormone (GHRH) while offering enhanced stability and prolonged half-life through binding to albumin via a Drug Affinity Complex (DAC). This modification allows for sustained elevation of endogenous GH and IGF-1 levels for up to a week following administration.

Research has focused on CJC-1295’s potential to stimulate pulsatile growth hormone release, promoting anabolic processes such as protein synthesis, lipolysis, and tissue repair. It has also been studied in contexts related to muscle recovery, metabolic health, and age-related hormonal decline. Unlike exogenous growth hormone administration, CJC-1295 supports the natural feedback-regulated GH axis, potentially reducing the risk of hormonal suppression.

Its long-acting profile and physiological mechanism make it a key candidate in experimental endocrinology, regenerative medicine, and aging-related research.